ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0377

The Prevalence of Inflammatory Back Pain and HLA-B27 in a Large Population-Based Cohort in the Netherlands

Stan Kieskamp, Suzanne Arends, Elisabeth Brouwer, Hendrika Bootsma, Ilja Nolte and Anneke Spoorenberg, University Medical Center Groningen, Groningen, Netherlands

Meeting: ACR Convergence 2021

Keywords: Back pain, Epidemiology, genetics, population studies, spondyloarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Aspects of Axial Spondyloarthritis (0357–0386)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Chronic low back pain (CLBP; back pain >3 months) with onset at age < 45 and inflammatory back pain (IBP) are regarded as early presenting and key features of axial spondyloarthritis (axSpA), and HLA-B27 as its most important genetic risk factor. Despite increasing familiarity with non-radiographic axSpA and the advent of Magnetic Resonance Imaging in demonstrating sacroiliitis, the long delay in axSpA diagnosis has not improved. The objective of this study was to explore the prevalence of CLBP and IBP in combination with HLA-B27 in the general population.

Methods: Participants of the Lifelines cohort, a large population-based cohort of the northern region of the Netherlands, filled out a questionnaire on chronic low back pain and IBP. Chronic low back pain was defined as an affirmative answer to the question ‘Did you suffer from low back pain for ≥3 months?’. IBP was questioned based on the validated European Spondyloarthropathy Study Group (ESSG) IBP criteria and was confirmed if at least 4 out of the following 5 criteria were present: (a) onset before age 45, (b) insidious onset, (c) improvement with exercise, (d) associated with morning stiffness, (e) at least 3 months duration. Participants reporting to have been diagnosed with axSpA were identified using variations of the search terms “Bechterew”, ”spondyloarthritis” and “ankylosing spondylitis”. The Illumina global screening array (GSA) beadchip-24 v1.0 was used to genotype genome-wide SNPs in a subset of Lifelines participants. HLA-B haplotypes were imputed using neighboring SNPs with HIBAG, which is an R-package, using published parameter estimates. The predicted HLA-B haplotype was considered valid if the posterior probability was >80%.

Results: 94.277 participants answered the question about CLBP, of which 22.804 (24.2%) participants reported CLBP. CLBP before the age of 45 could be identified in 17.481 (18.6%) participants. Of the 93.665 participants with ESSG questionnaire data available, 13.514 (14.4%) fulfilled the IBP criteria. HLA-B haplotype was determined with high prediction accuracy (posterior probability >0.8) in 29.399 Lifelines participants of which 2.279 (7.8%) were HLA-B27+. In the group of HLA-B27+ participants with CLBP (n=373; 23.2%), 238 (14.8%) also fulfilled the ESSG IBP criteria. Only 11 (4.6%) of these participants reported a previous axSpA diagnosis.

Conclusion: In this large Dutch population-based cohort, 7.8% were HLA-B27 positive, similar to earlier studies. Considerable underdiagnosis of axSpA may be expected since only a minor proportion of HLA-B27+ participants with CLBP fulfilling the ESSG IBP criteria reported to have been diagnosed with axSpA.


Disclosures: S. Kieskamp, Novartis, 5; S. Arends, None; E. Brouwer, Roche, 2, 6; H. Bootsma, Bristol Myers Squibb, 2, 5, 6, Roche, 2, 5, Novartis, 2, 6, Medimmune, 2, Union Chimique Belge, 2; I. Nolte, None; A. Spoorenberg, Novartis, 5, Abbvie, 2, Novartis, 2, Pfizer, 2, MSD, 2, UCB, 2, 5.

To cite this abstract in AMA style:

Kieskamp S, Arends S, Brouwer E, Bootsma H, Nolte I, Spoorenberg A. The Prevalence of Inflammatory Back Pain and HLA-B27 in a Large Population-Based Cohort in the Netherlands [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/the-prevalence-of-inflammatory-back-pain-and-hla-b27-in-a-large-population-based-cohort-in-the-netherlands/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-prevalence-of-inflammatory-back-pain-and-hla-b27-in-a-large-population-based-cohort-in-the-netherlands/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology